NCT03178357

Brief Summary

Hypertrophic cardiomyopathy (HCM) is the most common hereditary disease characterized by left ventricular hypertrophy and consequently left ventricular diastolic dysfunction. Its prevalence is estimated at around 0.2% in the general population. HCM is the most common cause of sudden cardiac death due to cardiovascular disease in young athletes, accounting for one third of deaths. HCM patients often have symptoms of heart failure. The ESC recommendations for heart failure (HF) from 2016 recommend exercise training regardless of ejection fraction to improve exercise capacity, quality of life, and reduction in hospitalizations due to HF. Meanwhile, for many years, HCM was equivalent to exercise training limitation. According to the 2014 ESC guidelines, it is recommended for patients with HCM to avoid sports practice. However the results of Edelmann et al. research, suggest that physical training leads to a significant clinical improvement in patients with diastolic dysfunction and thus may be beneficial in patients with HCM. In 2015 results of a first study were published (Klempfner et al.), which showed that the majority of HCM patients with moderate risk undergoing supervised physical training had improved physical performance and no significant adverse events were recorded. The study was limited by the small number of admitted patients (twenty), lack of control group and failure to perform cardio-pulmonary exercise test. The main goal of the study will be to evaluate the effectiveness and safety of comprehensive cardiological rehabilitation and telerehabilitation in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction with preserved systolic function. The study is planned to include 30 patients with HCM subjected to physical training and 30 patients with HCM in the control group treated as standard according to current guidelines, not subjected to physical training.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 6, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

July 10, 2017

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

March 26, 2019

Status Verified

March 1, 2019

Enrollment Period

3.4 years

First QC Date

June 5, 2017

Last Update Submit

March 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Peak VO2

    Physical efficiency evaluated in the measurable parameter - peak VO2.

    36 months

Study Arms (2)

HCM patients with CR

OTHER

30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)

Other: Cardiac rehabilitation + standard therapy

HCM patients without CR (control group)

OTHER

30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)

Other: Standard therapy

Interventions

Patients with HCM subjected to cardiological rehabilitation

Also known as: Standard therapy
HCM patients with CR

Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling

HCM patients without CR (control group)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with hypertrophic cardiomyopathy (defined in accordance with the ESC guidelines for the diagnosis and management of cardiomyopathy and hypertrophy in 2014): thickness ≥ 15 mm of one or more segments of the left ventricular wall measured using any imaging technique \[echocardiography, cardiac magnetic resonance or computed tomography\] which can not be explained solely by the left ventricular loading conditions) without left ventricular outflow tract obstruction at rest: gradient \<30 mmHg.
  • Stable general condition (1 month period).
  • NYHA Class II and III.
  • Preserved LV systolic function (LVEF ≥ 50%).
  • Condition after ICD implantation.
  • Written informed consent of the patient to participate in the Program.
  • Completed eighteen years of age.

You may not qualify if:

  • Complex life-threatening ventricular arrhythmias that can not be treated.
  • Uncontrolled hypertension.
  • Advanced atrio-ventricular block.
  • Myocarditis or pericarditis (up to 6 months).
  • Symptomatic aortic stenosis.
  • Acute systemic illness.
  • Intracardiac thrombosis.
  • Significant ischaemia during low intensity exercise test (2 METS, 50W).
  • Uncontrolled diabetes.
  • Pulmonary embolism (up to 6 months).
  • Thrombophlebitis.
  • New episode of AF/Afl.
  • Decrease in systolic blood pressure during exercise.
  • Co-morbidities that limit exercise tolerance and prevent exercise.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Cardinal Stefan Wyszyński Institute of Cardiology

Warsaw, Masovian Voivodeship, 04-628, Poland

RECRUITING

MeSH Terms

Interventions

Cardiac RehabilitationStandard of Care

Intervention Hierarchy (Ancestors)

RehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Krzysztof Sadowski

    The Cardinal Stefan Wyszyński Institute of Cardiology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Krzysztof R Sadowski, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2017

First Posted

June 6, 2017

Study Start

July 10, 2017

Primary Completion

December 1, 2020

Study Completion

December 1, 2020

Last Updated

March 26, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will not share

Locations